Fenoldopam (Corlopam) is a dopamine (D-1 receptor) agonist with minimal adrenergic effects. It is a rapidly acting vasodilator and is used in situations where a rapid decrease in the blood pressure is required such as hypertensive urgency and emergency.
Fenoldopam Uses:
-
Severe hypertension:
- It is for the short-term treatment of uncontrolled hypertension (up to 48 hours while the patient is in the hospital).
- It is also used to treat patients with malignant hypertension, in patients with deteriorating end-organ dysfunction secondary to uncontrolled hypertension, and for the reduction of blood pressure in children.
Fenoldopam (Corlopam) Dose in Adults
Fenoldopam (Corlopam) Dose in the treatment of Severe hypertension:
- It is administered intravenously at a dose of 0.01 - 0.3 mcg/kg/minute initially.
- Until the goal blood pressure is reached, the dose may be raised in increments of 0.05 to 0.1 mcg/kg/minute every 15 minutes.
- Clinical trials have revealed a maximal infusion rate of 1.6 mcg/kg/minute.
- The drug is usually administered for a period of 48 hours while the patient is in the hospital.
Note: Patients may continue oral antihypertensive medications while on treatment or after the infusion.
Fenoldopam (Corlopam) Dose in Children
Fenoldopam (Corlopam) Dose in the treatment of Severe hypertension:
-
Infants, Children, and Adolescents: IV:
- Continuous IV infusion:
- Starting with a continuous intravenous infusion of 0.2 mcg/kg/minute.
- Every 20 to 30 minutes, the dose may be raised by 0.3 to 0.5 mcg/kg/minute.
- 0.8 mcg/kg/minute is the maximum dose.
- Higher doses may not have additional blood pressure lowering effects and may worsen tachycardia.
- Continuous IV infusion:
Pregnancy Risk Factor B
- Only use it during pregnancy if clearly indicated.
- However, it has not yet been investigated in human pregnancies. Animal reproduction studies have not shown any evidence of fetal harm.
Fenoldopam use during breastfeeding:
- The data on the presence of the drug is not available.
- The manufacturer suggests that breastfeeding be stopped because of the possibility of serious side effects in infants breastfeeding with the drug.
- This is in line with the mother's rights and the risks to the infant from drug exposure.
Dose in Kidney Disease:
- The manufacturer has not recommended any dosage adjustment in the dose.
- The effects of hemodialysis on the drug have not been evaluated.
Dose in Liver disease:
The manufacturer has not recommended any dosage adjustment in the dose.
Side Effects of Fenoldopam (Corlopam):
-
Cardiovascular:
- Flushing
- Hypotension
-
Central nervous system:
- Headache
-
Gastrointestinal:
- Nausea
Less Common Side Effects of Fenoldopam (Corlopam):
-
Cardiovascular:
- Angina Pectoris
- Bradycardia
- Cardiac Failure
- Chest Pain
- ECG Abnormality (ST-T Abnormalities)
- Extrasystoles
- Inversion T Wave On ECG
- Myocardial Infarction
- Orthostatic Hypotension
- Palpitations
- Tachycardia
-
Central Nervous System:
- Anxiety
- Dizziness
- Insomnia
-
Dermatologic:
- Diaphoresis
-
Endocrine & Metabolic:
- Hyperglycemia
- Hypokalemia
- Increased Lactate Dehydrogenase
-
Gastrointestinal:
- Abdominal Distention
- Abdominal Pain
- Constipation
- Diarrhea
- Vomiting
-
Genitourinary:
- Oliguria
- Urinary Tract Infection
-
Hematologic & Oncologic:
- Hemorrhage
- Leukocytosis
-
Hepatic:
- Increased Serum Transaminases
-
Local:
- Injection Site Reaction
-
Neuromuscular & Skeletal:
- Back Pain
- Muscle Cramps (Limbs)
-
Ophthalmic:
- Increased Intraocular Pressure
-
Renal:
- Increased Blood Urea Nitrogen
- Increased Serum Creatinine
-
Respiratory:
- Dyspnea
- Nasal Congestion
-
Miscellaneous:
- Fever
Contraindications to Fenoldopam (Corlopam):
The manufacturer's labeling does not contain any contraindications.
Warnings and precautions
-
Hypokalemia
- Hypokalemia may occur in patients who receive the infusion within six hours.
- It is important to monitor potassium levels.
-
Tachycardia
- Tachycardia is possible, particularly if the rate of infusion exceeds 0.01 mcg/kg/minute for adults and 0.8 mg/kg/minute for children.
- Reflex tachycardia is less likely when the infusion rate is lower than 0.1 mg/kg/minute, and the drug is titrated slower.
-
Angina
- Tachycardia may occur due to an increase in myocardial oxygen requirement.
- Patients with obstructive or persistent coronary artery disease should not use it.
-
Glaucoma:
- Patients with intraocular hypertension and glaucoma may experience an increase in intraocular pressure that is dose-dependent.
- The intraocular pressure will return to baseline in two hours if the rate of infusion decreases.
Fenoldopam: Drug Interaction
Note: Drug Interaction Categories:
- Risk Factor C: Monitor When Using Combination
- Risk Factor D: Consider Treatment Modification
- Risk Factor X: Avoid Concomitant Use
Risk Factor C (Monitor therapy) |
|
Alfuzosin | May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
Amphetamines | May lessen the effectiveness of antihypertensive agents. |
Antipsychotic Agents (Second Generation [Atypical]) | Antipsychotic drugs' hypotensive effects may be enhanced by blood pressure-lowering medications (Second Generation [Atypical]).. |
Barbiturates | The hypotensive effects of blood pressure-lowering medications may be strengthened. |
Benperidol | The hypotensive effects of blood pressure-lowering medications may be strengthened. |
Brigatinib | May lessen the effectiveness of antihypertensive agents. Antihypertensive Agents' bradycardic action may be strengthened by brutinib. |
Brimonidine (Topical) | The hypotensive effects of blood pressure-lowering medications may be strengthened. |
Dexmethylphenidate | May lessen the effectiveness of antihypertensive agents. |
Diazoxide | The hypotensive effects of blood pressure-lowering medications may be strengthened. |
DULoxetine | The hypotensive impact of DULoxetine may be enhanced by blood pressure lowering medications. |
Herbs (Hypertensive Properties) | May lessen the effectiveness of antihypertensive agents. |
Herbs (Hypotensive Properties) | The hypotensive effects of blood pressure-lowering medications may be strengthened. |
Hypotension-Associated Agents | The hypotensive action of hypotension-associated agents may be strengthened by blood pressure lowering medications. |
Levodopa-Containing Products | Levodopa-Containing Products' hypotensive effects may be strengthened by blood pressure-lowering medications. |
Lormetazepam | The hypotensive effects of blood pressure-lowering medications may be strengthened. |
Methylphenidate | May lessen the effectiveness of antihypertensive agents. |
Molsidomine | The hypotensive effects of blood pressure-lowering medications may be strengthened. |
Naftopidil | The hypotensive effects of blood pressure-lowering medications may be strengthened. |
Nicergoline | May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
Nicorandil | May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
Nitroprusside | Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. |
Pentoxifylline | May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
Pholcodine | Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. |
Phosphodiesterase 5 Inhibitors | May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
Prostacyclin Analogues | The hypotensive effects of blood pressure-lowering medications may be strengthened. |
Quinagolide | The hypotensive effects of blood pressure-lowering medications may be strengthened. |
Yohimbine | May lessen the effectiveness of antihypertensive agents. |
Risk Factor D (Consider therapy modification) |
|
Amifostine | Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered. |
Obinutuzumab | May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. |
Risk Factor X (Avoid combination) |
|
Bromperidol | May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. |
Monitoring parameters:
- Blood pressure,
- heart rate,
- ECG
- serum potassium concentrations
How to administer Fenoldopam (Corlopam)?
It's given as an ongoing intravenous infusion.
Fenoldopam Mechanism of action:
It is a particular type of dopaminergic post-synaptic agonist (D-1-receptors). It produces quick-acting hypotensive effects through:
- decreasing peripheral vascular resistance and increased renal blood flow,
- diuresis, and
- natriuresis;
It has little adrenergic activity and is six times more effective than dopamine at causing renal vascular dilatation.
The start of an intravenous drug's effects:
- Children: 5 minutes;
- Adults: 10 minutes;
- Note: Most of the effects of the drug can be seen within 15 minutes.
Duration of action: IV:
- 1 hour
Half-life elimination: IV:
- Children: 3 to 5 minutes;
- Adults: about 5 minutes
Metabolism:
- It undergoes methylation, glucuronidation, and sulfation in the liver, and the 8-sulfate metabolite may have some action;
- It has a significant first-pass impact.
Excretion:
- Urine (90%);
- feces (10%)
International Brand Names of Fenoldopam:
- Corlopam
Fenoldopam Brand Names in Pakistan:
No Brands Available in Pakistan.